BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 10646844)

  • 1. Loss of fragile histidine triad expression in colorectal carcinomas and premalignant lesions.
    Hao XP; Willis JE; Pretlow TG; Rao JS; MacLennan GT; Talbot IC; Pretlow TP
    Cancer Res; 2000 Jan; 60(1):18-21. PubMed ID: 10646844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Abnormal expression of fragile histidine triad (FHIT) and Mut S homolog 2 (MSH2) proteins in human sporadic colorectal carcinoma and their clinical significance].
    Yao CC; Lin CY; Hu MB
    Ai Zheng; 2004 Mar; 23(3):310-6. PubMed ID: 15025965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of Fhit expression in development of colorectal carcinoma of various macroscopic types.
    Kuwai T; Tanaka S; Kaio E; Hiyama T; Ito M; Kitadai Y; Sumii M; Yoshihara M; Haruma K; Chayama K
    Int J Mol Med; 2003 Oct; 12(4):437-42. PubMed ID: 12964015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of FHIT function in lung cancer and preinvasive bronchial lesions.
    Sozzi G; Pastorino U; Moiraghi L; Tagliabue E; Pezzella F; Ghirelli C; Tornielli S; Sard L; Huebner K; Pierotti MA; Croce CM; Pilotti S
    Cancer Res; 1998 Nov; 58(22):5032-7. PubMed ID: 9823304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors.
    Greenspan DL; Connolly DC; Wu R; Lei RY; Vogelstein JT; Kim YT; Mok JE; Muñoz N; Bosch FX; Shah K; Cho KR
    Cancer Res; 1997 Nov; 57(21):4692-8. PubMed ID: 9354423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent altered expression of fragile histidine triad protein in human colorectal adenomas.
    Morikawa H; Nakagawa Y; Hashimoto K; Niki M; Egashira Y; Hirata I; Katsu K; Akao Y
    Biochem Biophys Res Commun; 2000 Nov; 278(1):205-10. PubMed ID: 11071873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fragile histidine triad (FHIT) gene is overexpressed in colorectal cancer.
    Wierzbicki PM; Adrych K; Kartanowicz D; Dobrowolski S; Stanislawowski M; Chybicki J; Godlewski J; Korybalski B; Smoczynski M; Kmiec Z
    J Physiol Pharmacol; 2009 Oct; 60 Suppl 4():63-70. PubMed ID: 20083853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fragile histidine triad expression in oral squamous cell carcinoma and precursor lesions.
    Kujan O; Oliver R; Roz L; Sozzi G; Ribeiro N; Woodwards R; Thakker N; Sloan P
    Clin Cancer Res; 2006 Nov; 12(22):6723-9. PubMed ID: 17121892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-regulation of FHIT inhibits apoptosis of colorectal cancer: mechanism and clinical implication.
    Cao J; Li W; Xie J; Du H; Tang W; Wang H; Chen X; Xiao W; Li Y
    Surg Oncol; 2006 Dec; 15(4):223-33. PubMed ID: 17382535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered expression of Fhit in carcinoma and precarcinomatous lesions of the esophagus.
    Mori M; Mimori K; Shiraishi T; Alder H; Inoue H; Tanaka Y; Sugimachi K; Huebner K; Croce CM
    Cancer Res; 2000 Mar; 60(5):1177-82. PubMed ID: 10728669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beta-catenin expression is altered in human colonic aberrant crypt foci.
    Hao XP; Pretlow TG; Rao JS; Pretlow TP
    Cancer Res; 2001 Nov; 61(22):8085-8. PubMed ID: 11719432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The expression of Fhit protein is related inversely to disease progression in patients with breast carcinoma.
    Gatalica Z; Lele SM; Rampy BA; Norris BA
    Cancer; 2000 Mar; 88(6):1378-83. PubMed ID: 10717620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Expression and significance of fragile histidine triad in oral cancer and precancerous lesions].
    Yin C; Shen LJ; Xie SM; Ruan P; Yao X
    Di Yi Jun Yi Da Xue Xue Bao; 2005 May; 25(5):584-6. PubMed ID: 15897145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical expression of Fhit protein in Helicobacter pylori related chronic gastritis, gastric precancerous lesions and gastric carcinoma: correlation with conventional clinicopathologic parameters.
    Skopelitou AS; Mitselou A; Katsanos KH; Alexopoulou V; Tsianos EV
    Eur J Gastroenterol Hepatol; 2003 May; 15(5):515-23. PubMed ID: 12702909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered expression of the fragile histidine triad gene in primary gastric adenocarcinomas.
    Lee SH; Kim WH; Kim HK; Woo KM; Nam HS; Kim HS; Kim JG; Cho MH
    Biochem Biophys Res Commun; 2001 Jun; 284(3):850-5. PubMed ID: 11396980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of FHIT expression in breast cancer is correlated with poor prognostic markers.
    Arun B; Kilic G; Yen C; Foster B; Yardley DA; Gaynor R; Ashfaq R
    Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1681-5. PubMed ID: 16030101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological significance of the fragile histidine triad transcription protein expression in laryngeal carcinogenesis.
    Kitamura K; Hayashi K; Kobayashi R; Ishii H; Matsubayashi J; Matsumoto T; Suzuki M
    Oncol Rep; 2008 Apr; 19(4):847-52. PubMed ID: 18357366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma.
    Guler G; Uner A; Guler N; Han SY; Iliopoulos D; Hauck WW; McCue P; Huebner K
    Cancer; 2004 Apr; 100(8):1605-14. PubMed ID: 15073846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of Msh2 protein expression is associated with alteration in the FHIT locus and Fhit protein expression in colorectal carcinoma.
    Mori M; Mimori K; Masuda T; Yoshinaga K; Yamashita K; Matsuyama A; Inoue H
    Cancer Res; 2001 Oct; 61(20):7379-82. PubMed ID: 11606365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Loss of fragile histidine triad expression and metastasis in breast cancer].
    Zhao P; Li XY; Chen LZ
    Ai Zheng; 2002 Jun; 21(6):668-70. PubMed ID: 12452072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.